Harel Insurance Investments & Financial Services Ltd. Autolus Therapeutics PLC Transaction History

Harel Insurance Investments & Financial Services Ltd.

$5.8 Billion
Q3 2024

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q4 2018 Jan 29, 2019	SELL	$24.21 - $48.01 $36,097 - $71,582	-1,491 Closed	0 $0
Q3 2018 Oct 29, 2018	BUY	$20.86 - $33.33 $31,102 - $49,695	1,491 New	1,491 $46,000

Others Institutions Holding AUTL

# of Institutions

104

Shares Held

163M

Call Options Held

2.8K

Put Options Held

13.4K

Wellington Management Group LLP Boston, MA

24.2M
Shares

$72.4 Million
0.02% of portfolio
Blackstone Inc New York, NY

20.5M
Shares

$61.3 Million
0.35% of portfolio
Syncona Portfolio LTD Guernsey, Channel Islands, X0

18.6M
Shares

$55.5 Million
83.42% of portfolio
Deep Track Capital, LP Greenwich, CT

15.3M
Shares

$45.7 Million
2.04% of portfolio
Avoro Capital Advisors LLC New York, NY

12.3M
Shares

$36.9 Million
0.67% of portfolio

View Full List

About Autolus Therapeutics plc

Ticker AUTL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 90,909,800
Market Cap $272M
Description
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which...

More about AUTL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Harel Insurance Investments & Financial Services Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Harel Insurance Investments & Financial Services Ltd. with notifications on news.

Account